Formulation and evaluation of mucoadhesive tablets containing eugenol for the treatment of periodontal diseases.
about
Intercultural Usage of Mori Folium: Comparison Review from a Korean Medical PerspectiveEmbryotoxicity estimation of commonly used compounds with embryonic stem cell test.Hydrocolloid-based nutraceutical delivery systems: Effect of counter-ions on the encapsulation and release.Phytonutrient diet supplementation promotes beneficial Clostridia species and intestinal mucus secretion resulting in protection against enteric infectionIntra-pocket anaesthesia and pain during probing, scaling and root planing: a systematic review and meta-analysis.Essential Oils and Eugenols Inhibit Biofilm Formation and the Virulence of Escherichia coli O157:H7.Crystal structures of two platinum(II) complexes containing ethyl eugenoxyacetate and 2-amino-pyridine.Treatment modalities and evaluation models for periodontitisClove (Eugenia aromatica) and clove oil (eugenol). Natural standard monograph (www.naturalstandard.com) copyright © 2008.Eugenol nanocapsule for enhanced therapeutic activity against periodontal infections.Chemical Compositions and Antimicrobial Activities of Ocimum sanctum L. Essential Oils at Different Harvest Stages.In vitro inhibitory effect of clove essential oil and its two active principles on tooth decalcification by apple juice.Pharmacokinetics and anesthetic activity of eugenol in male Sprague-Dawley rats.Topical anti-inflammatory constituents of lipophilic leaf fractions of Alchornea floribunda and Alchornea cordifolia.Antifungal activity of synthetic antiseptics and natural compounds against Candida dubliniensis before and after in vitro fluconazole exposure.Cytotoxicity and antimicrobial action of selected phytochemicals against planktonic and sessile Streptococcus mutans.
P2860
Q26779376-7F9E92C1-6906-4B0E-9770-65B195DC84DFQ33827971-5DCA14AB-4388-49E2-9FA1-C309137E9113Q34533808-9DCD6220-9FC4-4B16-8281-C324A01663FAQ35193689-DBDA423B-C6D9-45C5-91F2-422A9FCEA1CAQ35995044-9001E100-9690-43EB-9404-44F1CB96AAB7Q37390154-C977A20F-771E-4AE7-9B3A-C7E49F54EE3AQ37739519-81F00902-8EA6-4A6A-AA30-5E909A2E81D9Q38078370-FF423EB5-0F1C-4C08-A34B-B6BF612267A1Q40430591-5D85CF22-1082-4893-8D6D-977A0FFF84B7Q41157981-70F2B27F-5F66-42B0-B609-15FA15E11D43Q41436431-69093DFE-EEAD-4662-808D-FA2C63EE2019Q42322517-E1F7E286-EED1-4CB2-986E-6B397261D27CQ48681780-80012675-B622-4BC9-A49C-A654EE253595Q50596054-D6B91586-FFDA-4A36-AAB0-95CDF3D83332Q53746699-047E4925-C73B-45E9-8C05-E82A72610B3BQ55360931-A3EAE5F5-C036-401D-AA6C-220857ED3A96
P2860
Formulation and evaluation of mucoadhesive tablets containing eugenol for the treatment of periodontal diseases.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Formulation and evaluation of ...... tment of periodontal diseases.
@ast
Formulation and evaluation of ...... tment of periodontal diseases.
@en
Formulation and evaluation of ...... tment of periodontal diseases.
@nl
type
label
Formulation and evaluation of ...... tment of periodontal diseases.
@ast
Formulation and evaluation of ...... tment of periodontal diseases.
@en
Formulation and evaluation of ...... tment of periodontal diseases.
@nl
prefLabel
Formulation and evaluation of ...... tment of periodontal diseases.
@ast
Formulation and evaluation of ...... tment of periodontal diseases.
@en
Formulation and evaluation of ...... tment of periodontal diseases.
@nl
P2093
P2860
P356
P1476
Formulation and evaluation of ...... tment of periodontal diseases.
@en
P2093
Anant R Ketkar
Bhimrao K Jadhav
Kishanchandra R Khandelwal
Sambhaji S Pisal
P2860
P304
P356
10.1081/DDC-120028715
P407
P577
2004-02-01T00:00:00Z